for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Carmat SA

ALCAR.PA

Latest Trade

17.40EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

17.32

 - 

28.90

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
17.40
Open
--
Volume
--
3M AVG Volume
0.22
Today's High
--
Today's Low
--
52 Week High
28.90
52 Week Low
17.32
Shares Out (MIL)
9.43
Market Cap (MIL)
220.37
Forward P/E
-3.61
Dividend (Yield %)
--

Latest Developments

More

Carmat: Raises EUR 60 Mln In Share Issue At EUR 19/Shr

Carmat Launches Capital Raise Of Minimum EUR 50 Mln

Carmat H1 Net Loss Widens To 24.0 Million Euros

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Carmat SA

Carmat SAS is a France-based Company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels and Blood Institute, Laboratoire de Recherche Biochirurgicale and others. As of December 31, 2011, a company MATRA DEFENSE held a 30.57% stake in the Company’s shareholdings.

Industry

Medical Equipment & Supplies

Contact Info

36

avenue de l'Europe, Immeuble l'Etendard

+33.1.39456450

http://www.carmatsa.com/

Executive Leadership

Jean-Pierre Garnier

Chairman of the Board

Stephane Piat

Chief Executive Officer, Director

Pascale d'Arbonneau

Chief Financial Officer, Chief Administrative Officer, IR Contact Officer

Marc Grimme

Technical Director

Eric Richez

Director of Business Development

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-3.810

2017

-3.240

2019(E)

-4.845
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
439.72
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4,123.50
LT Debt To Equity (MRQ)
4,123.50
Return on Investment (TTM)
-147.55
Return on Equity (TTM)
-115.73

Latest News

Latest News

BRIEF-Carmat Continuing Progress In Line With Objective Of Obtaining CE Marking In 2019

* OPENING OF NEW BOIS-D'ARCY SITE FOR LARGE-SCALE PRODUCTION OF PROSTHESES

BRIEF-Carmat Says To Keep Patient Enrollment Pace In Line With Its Goal To Finalize Pivotal Study By Year-End

* SAYS ADVANCES THE INTERNATIONALIZATION OF THE PIVOTAL STUDY AND OBTAINS THE APPROVAL TO PERFORM IMPLANTS IN DENMARK

BRIEF-Carmat To Internationalize PIVOTAL Study And To Perform Implants In Denmark

* CARMAT ADVANCES THE INTERNATIONALIZATION OF THE PIVOTAL STUDY AND OBTAINS THE APPROVAL TO PERFORM IMPLANTS IN DENMARK Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-‍Carmat Launches A Capital Increase For An Initial Amount Of EUR 46 Million​

* CARMAT LAUNCHES A CAPITAL INCREASE FOR AN INITIAL AMOUNT OF EUR 46 MILLION

BRIEF-Carmat Launches Capital Increase For Initial Amount Of 46 Million Euros

* LAUNCHES A CAPITAL INCREASE WITHOUT SHAREHOLDERS’ PREFERENTIAL SUBSCRIPTION RIGHTS AND WITH A 4-TRADING DAY PRIORITY SUBSCRIPTION PERIOD ON AN IRREDUCIBLE BASIS TO SHAREHOLDERS FOR AN INITIAL AMOUNT OF €46 MILLION

BRIEF-Carmat: First Implantation In Czech Republic Within Framework Of Pivotal Study International Expansion

* FIRST IMPLANTATION IN THE CZECH REPUBLIC WITHIN THE FRAMEWORK OF THE PIVOTAL STUDY INTERNATIONAL EXPANSION

BRIEF-Carmat signs a partnership agreement with AddUp

* CARMAT SIGNS A PARTNERSHIP AGREEMENT WITH ADDUP, THE MICHELIN AND FIVES JOINT VENTURE SPECIALIZED IN 3D PRINTING

BRIEF-Carmat's artificial heart implanted in Kazakhstan

* IMPLANTATION WAS PERFORMED AT NATIONAL RESEARCH CENTER FOR CARDIAC SURGERY IN ASTANA, KAZAKHSTAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Carmat expands pivotal study internationally

* CARMAT EXPANDS ITS PIVOTAL STUDY INTERNATIONALLY, IN LINE WITH ITS CLINICAL STRATEGY AND CE MARKING PROCESS

BRIEF-Carmat reports H1 operating expenses of 14.7 million euros

* CONFIRMATION OF OBJECTIVE OF COMPLETING PIVOTAL STUDY AT END OF 2018

French implant maker Carmat pins hopes on low energy heart

Artificial heart maker Carmat is hoping a more energy-efficient implant and the appointment of a production chief can help it overcome recent failures at the French firm.

Carmat buoyed by approval to resume artificial heart trial

Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume a heart implant trial, sending the company's shares more than one fifth higher on Wednesday.

Carmat gets approval to resume artificial heart implants trial

Artificial heart maker Carmat has obtained approval from France's national drugs agency (ANSM) to resume heart implant trials, the company said on Tuesday.

BRIEF-Carmat FY net loss widens to 23 million euros

* Solid cash position of 31.2 million euros ($33.13 million) at December 31, 2016

Carmat withdraws initial request to resume artificial heart implants

Artificial heart maker Carmat said on Monday it had decided to withdraw its initial request to France's national drugs agency (ANSM) to resume trial implantations.

Carmat withdraws initial request to resume artificial heart implants

Artificial heart maker Carmat said on Monday it had decided to withdraw its initial request to France's national drugs agency (ANSM) to resume trial implants.

Carmat shares slump after France halts heart implants

Shares in artificial heart maker Carmat slumped on Thursday after France's national drugs agency ordered it to suspend further implants following the death of a patient in October.

French drugs agency suspends new Carmat artificial heart implants

France's national drugs agency said on Wednesday it had ordered artificial heart maker Carmat to suspend further implants after a fifth patient died in October.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up